Biomedical Advanced Research and Development Authority (BARDA)

Biomedical Advanced Research and Development Authority (BARDA)

An American government organization with a focus on researching and developing countermeasures for health security threats. It was founded in 2006 and is located in Washington, D.C.

The Biomedical Advanced Research and Development Authority (BARDA) is a Washington, D.C.-based government organization that facilitates the process of developing drugs and vaccines for serious health concerns, such as Ebola and COVID-19, by investing money in companies that are already doing the research. It also invests in therapies, non-pharmaceutical countermeasure, and diagnostic tools that may aid in public health emergencies. BARDA supports the development of countermeasures forchemical, biological, radiological, and nuclear(CBRN) threats such as anthrax, botulism, smallpox, nerve agents, radiation as well as pandemic influenza and emerging infectious diseases.

Organization

BARDA was formed with the stated intention of protecting the United States of America from chemical, biological, radiological, and nuclear (CBRN) threats as well as pandemic influenza and emerging infectious diseases. The organization aids other entities which are developing products and/or medicines to combat the aforementioned issues via an advanced development pipeline. It states that it seeks to make public-private partnerships. Aid from BARDA comes in the form of funding, technical assistance (such as clinical research organization networking), and fill-finishing networking.

History

BARDA was established in 2006, as part of a response to the need for medical countermeasures like vaccines, therapeutics and diagnostics to protect US citizens from chemical, biological, radiological and nuclear (CBRN) threats. The need was highlighted after the 9/11 attacks on Americans and the subsequent 2001 anthrax attacks through the mail. The BioShield Act of 2004 aimed to augment market incentives for companies pursuing the development of chemical, biological, radiological and nuclear (CBRN) threats, and the Pandemic All Hazards Preparedness Act of 2006 (PAHPA) established BARDA under the Assistant Secretary for Preparedness and Response. BARDA was established to focus on development and procurement of medical countermeasures for CBRN threats, pandemic influenza, and emerging infectious diseases. BARDA received funding at $415 million annually from 2014-2018 by the PAHPA of 2013. The funding was used to mobilize pharmaceutical and biotechnology companies to pursue development of countermeasures to CBRN threats.

COVID-19

Countermeasures to the COVID-19 pandemic caused by SARS-CoV-2 coronavirus supported by BARDA include diagnostics, vaccines, therapeutics, ventilators, respiratory protective devices and advanced manufacturing technologies. BARDA's portfolio of partners in COVID-19 countermeasures is available at the Medical Countermeasures.gov.

Timeline

May 21, 2020
U.S. gives up to $1.2 billion to AstraZeneca for Covid-19 vaccine

AstraZeneca will begin late-stage clinical trials this summer with roughly 30,000 people in the U.S. and is part of the Operation Warp Speed program to accelerate Covid-19 medical products to the American public.The arrangement with AstraZeneca is labeled a public-private partnership and BARDA will provide technology transfers and scaled-up manufacturing.

April 16, 2020
Moderna Inc said on Thursday that it received a $483 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development of its vaccine candidate for the novel coronavirus.
2016
BARDA will procure Emergent BioSolutions’ AV7909 anthrax vaccine in Strategic National Stockpile

The company's AV7909 development and procurement contract with BARDA, valued at up to $1.5 billion, was signed in 2016.

July 3, 2006
Establishment of BARDA the by Pandemic All Hazards Preparedness Act of 2006 (PAHPA)
July 3, 2004
The Project BioShield Act of 2004 was signed into law to fundamentally augment market incentives for companies pursuing the development of CBRN medical countermeasures
September 18, 2001
Letters laced with deadly anthrax spores began arriving at media companies and congressional offices, resulting in five deaths and infection in 17 others
September 11, 2001
Terrorists hijack four airline jets and crash them into the World Trade Center towers in New York City, the Pentagon in Virginia and a field in rural Somerset County, Pa.

People

Name
Role
LinkedIn

Gary L. Disbrow

Acting Director

Further reading

Title
Author
Link
Type
Date

BARDA: The venture capital firm buried in the U.S. government - Marketplace

Dan Gorenstein

Web

October 30, 2014

J&J allies with BARDA to accelerate coronavirus vaccine program

Nick Paul Taylor

Web

February 12, 2020

Documentaries, videos and podcasts

Title
Date
Link

BARDA: An Introduction

October 13, 2011

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
November 14, 2020
BioSpace
Johnson & Johnson announced the expansion to the partnership between its Janssen Pharmaceutical Companies and the Biomedical Advanced Research and Development Authority, which is part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services for the ongoing development of Janssen's investigational COVID-19 vaccine candidate.
Johnson & Johnson
November 14, 2020
www.prnewswire.com:443
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) announced the expansion to the partnership between its Janssen Pharmaceutical Companies (Janssen)...

References

Page 1 of 2
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.